Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New Patient Study Suggests Siemens Non-Invasive Blood Test May Have a Role in Monitoring Breast Cancer Patients' Response to Herceptin* (trastuzumab) Therapy
December 4th, 2008
Siemens Healthcare (www.siemens.com/diagnostics) announced that data from a new study published in the American Cancer Society journal Cancer, supports using the Siemens Serum HER-2/neu test to monitor patients with an aggressive type of metastatic breast cancer. This non-invasive blood test can be used to help monitor the widely-used Herceptin(R) therapy. Metastatic cancer is an advanced stage of cancer that has spread to one or more sites throughout the body. As recommended by the National Comprehensive Cancer Network (NCCN), clinicians should determine if a metastatic breast cancer (MBC) patient carries a protein called HER-2/neu, which is associated with an...
Source: Women's Health Weekly (2008-12-04)
|
